Indivior Pharmaceuticals Inc (INDV) FinancialsINDVFinancialIndivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc (INDV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SUBLOCADE, accounting for 64.2% of total sales, equivalent to $192.00M. Other significant revenue streams include Sublingual/Other and PERSERIS. Understanding this composition is critical for investors evaluating how INDV navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Indivior Pharmaceuticals Inc maintains a gross margin of 85.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 46.65%, while the net margin is 35.57%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively INDV converts its operational activities into shareholder value.

In the context of the broader market, INDV competes directly with industry leaders such as MANE and BDRX. With a market capitalization of $4.60B, it holds a significant position in the sector. When comparing efficiency, INDV's gross margin of 85.42% stands against MANE's N/A and BDRX's N/A. Such benchmarking helps identify whether Indivior Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Indivior has shown strong financial performance with a net income of $122 million in Q2 2026, and a gross margin of 85.42%, indicating robust profitability.